First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

Johnson & Johnson (J&J) can now offer rheumatoid arthritis (RA) patients in the US an alternative to its subcutaneous version of Simponi after regulators approved the intravenous version Simponi Aria.

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each ...

Simponi and Simponi Aria (golimumab) can cause mild to serious side effects. A more common side effect includes upper respiratory infection. If side effects from the drug become difficult to tolerate, ...

Johnson & Johnson’s biotech arm, Janssen Biotech, received an expanded indication for its anti-TNF (tumor necrosis factor) infusion therapy, Simponi Aria (golimumab), for patients with ...

SIMPONI ARIA (golimumab) 50mg/4mL single-use vial Simponi Aria (golimumab for infusion; Janssen Biotech) has received approval from the FDA for the treatment of adults with moderately to severely ...

Please provide your email address to receive an email when new articles are posted on . Janssen announced it has received FDA approvals for Simponi Aria for the treatment of adults with psoriatic ...

rheumatoid arthritis and ankylosing spondylitis in adults psoriatic arthritis in adults and children ages 2 years and older polyarticular juvenile idiopathic arthritis in children ages 2 years and ...

What Is Simponi, and Why Does It Matter? The FDA has approved Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kilograms (33 pounds).

Simponi is also prescribed to treat ulcerative colitis in adults. And Simponi Aria is also prescribed to treat PsA and polyarticular juvenile idiopathic arthritis in some children. Simponi and Simponi ...